Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Liabilities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Total Liabilities for 15 consecutive years, with $107.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 26.14% to $107.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.8 million through Dec 2025, up 26.14% year-over-year, with the annual reading at $105.2 million for FY2025, 16.41% up from the prior year.
  • Total Liabilities for Q4 2025 was $107.8 million at Aytu Biopharma, up from $101.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $128.1 million in Q2 2021, with the low at $85.5 million in Q4 2024.
  • Average Total Liabilities over 5 years is $101.4 million, with a median of $100.7 million recorded in 2023.
  • The sharpest move saw Total Liabilities soared 131.5% in 2021, then decreased 27.15% in 2022.
  • Over 5 years, Total Liabilities stood at $118.3 million in 2021, then decreased by 19.16% to $95.6 million in 2022, then grew by 2.9% to $98.4 million in 2023, then decreased by 13.14% to $85.5 million in 2024, then grew by 26.14% to $107.8 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $107.8 million, $101.8 million, and $105.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.